Search for other papers by Xiaomei Zhang in
Google Scholar
PubMed
Search for other papers by Zhangrong Xu in
Google Scholar
PubMed
Search for other papers by Xingwu Ran in
Google Scholar
PubMed
Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, China
Search for other papers by Linong Ji in
Google Scholar
PubMed
, % ( n ) 47.2 (3923) 62.2 (579) 45.3 (3345) ≤0.001 Antiplatelet therapy, % ( n ) 38.6 (3205) 46.6 (434) 37.5 (2771) ≤0.001 Statins therapy, % ( n ) 45.5 (3780) 47.5 (442) 45.2 (3338) 0.196 Table 2
Search for other papers by Julia Otten in
Google Scholar
PubMed
Region Jönköping County, Jönköping, Sweden
Search for other papers by Andreas Stomby in
Google Scholar
PubMed
Search for other papers by Maria Waling in
Google Scholar
PubMed
Search for other papers by Elin Chorell in
Google Scholar
PubMed
Search for other papers by Mats Ryberg in
Google Scholar
PubMed
Search for other papers by Michael Svensson in
Google Scholar
PubMed
Search for other papers by Jens Juul Holst in
Google Scholar
PubMed
Search for other papers by Tommy Olsson in
Google Scholar
PubMed
blood pressure, mmHg 84 (77–92) Total cholesterol, mmol/L (ref 3.9–7.8) 4.3 (3.6–4.9) LDL, mmol/L (ref 2.0–5.3) 2.2 (1.7–2.8) Triglycerides, mmol/L (ref < 2.6) 1.9 (1.2–2.8) Metformin therapy 20 Statin therapy 14
Search for other papers by Thera P Links in
Google Scholar
PubMed
Search for other papers by Trynke van der Boom in
Google Scholar
PubMed
Search for other papers by Wouter T Zandee in
Google Scholar
PubMed
Search for other papers by Joop D Lefrandt in
Google Scholar
PubMed
, Mihaylova B Emberson J Blackwell L Keech A Simes J Barnes EH Voysey M Gray A Collins R The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27
Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland
Search for other papers by Milica Popovic in
Google Scholar
PubMed
Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland
Search for other papers by Fahim Ebrahimi in
Google Scholar
PubMed
Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland
Search for other papers by Sandrine Andrea Urwyler in
Google Scholar
PubMed
Department of Biomedicine, University of Basel, Basel, Switzerland
Search for other papers by Marc Yves Donath in
Google Scholar
PubMed
Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland
Search for other papers by Mirjam Christ-Crain in
Google Scholar
PubMed
.5) 14 (42.4) Treatment with statins 35 (47.9) 11 (33.3) 7 (21.2) Antidepressive medication 11 (15.1) 1 (3.0) 1 (3.0) Antipsychotic medication 1 (1.4) 0 (0.0) 0 (0.0) Variables are summarized as mean ( s
Search for other papers by Frederique Van de Velde in
Google Scholar
PubMed
Search for other papers by Marlies Bekaert in
Google Scholar
PubMed
Search for other papers by Anja Geerts in
Google Scholar
PubMed
Search for other papers by Anne Hoorens in
Google Scholar
PubMed
Search for other papers by Arsène-Hélène Batens in
Google Scholar
PubMed
Search for other papers by Samyah Shadid in
Google Scholar
PubMed
Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany
German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
Search for other papers by Margriet Ouwens in
Google Scholar
PubMed
Search for other papers by Yves Van Nieuwenhove in
Google Scholar
PubMed
Search for other papers by Bruno Lapauw in
Google Scholar
PubMed
values are shown for differences between the three SAF groups, significant P values were indicated in bold. a 24 patients were excluded from analysis due to use of statins. b One patient is excluded as it had an extreme high value (TG = 16
Department of Research and Development, Region Kronoberg, Växjö, Sweden
Region Kronoberg, Primary Care, Växjö, Sweden
Search for other papers by Eva Olga Melin in
Google Scholar
PubMed
Search for other papers by Jonatan Dereke in
Google Scholar
PubMed
Department of Research and Development, Region Kronoberg, Växjö, Sweden
Department of Internal Medicine, Endocrinology and Diabetes, Central Hospital, Växjö, Sweden
Search for other papers by Maria Thunander in
Google Scholar
PubMed
Search for other papers by Magnus Hillman in
Google Scholar
PubMed
(statins) (C10AA). Indications for LLD were TC >4.5 mmol/l (>1.74 mg/dl) and/or LDL >2.5 mmol/l (>97 mg/dl) according to the Swedish national guidelines in 2009 ( 33 ). AHD were calcium antagonists (ATC codes bib8CA01-02); ACE inhibitors (ATC codes bib9AA
Search for other papers by Eng-Loon Tng in
Google Scholar
PubMed
Search for other papers by Yee Sian Tiong in
Google Scholar
PubMed
Search for other papers by Aye Thida Aung in
Google Scholar
PubMed
Search for other papers by Nicole Ya Yuan Chong in
Google Scholar
PubMed
Search for other papers by Zhemin Wang in
Google Scholar
PubMed
-BLED score was not stated.Baseline characteristics of TAF and non-thyroid AF patients were compared. There were statistically significant differences in ACEI/ARB, beta blocker, digoxin, and statin use between groups. IS, mortality, major bleeding
Section of Pacing and Electrophysiology, Division of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Search for other papers by Ling Sun in
Google Scholar
PubMed
Search for other papers by Wenwu Zhu in
Google Scholar
PubMed
Search for other papers by Yuan Ji in
Google Scholar
PubMed
Search for other papers by Ailin Zou in
Google Scholar
PubMed
Dalian Medical University, Dalian, Liaoning, China
Search for other papers by Lipeng Mao in
Google Scholar
PubMed
Dalian Medical University, Dalian, Liaoning, China
Search for other papers by Boyu Chi in
Google Scholar
PubMed
Search for other papers by Jianguang Jiang in
Google Scholar
PubMed
Search for other papers by Xuejun Zhou in
Google Scholar
PubMed
Search for other papers by Qingjie Wang in
Google Scholar
PubMed
Search for other papers by Fengxiang Zhang in
Google Scholar
PubMed
.783 β-blocker 738 (58.8%) 144 (64.3%) 0.12 438 (65.2%) 144 (64.3%) 0.872 Statins 1127 (89.7%) 195 (87.1%) 0.232 599 (89.1%) 195 (87.1%) 0.466 Low molecular heparin 1233 (98.2%) 216 (96.4%) 0.094 653 (97
Diabetes and Endocrine Unit, National Hospital, Kandy, Sri Lanka
Search for other papers by G Amiyangoda in
Google Scholar
PubMed
Search for other papers by C N Antonypillai in
Google Scholar
PubMed
Search for other papers by S S C Gunatilake in
Google Scholar
PubMed
Search for other papers by T T Weerathunge in
Google Scholar
PubMed
Search for other papers by D Ediriweera in
Google Scholar
PubMed
Search for other papers by S G P D Kosgallana in
Google Scholar
PubMed
Search for other papers by R D P Jayawardana in
Google Scholar
PubMed
Search for other papers by H A N D Thissera in
Google Scholar
PubMed
Search for other papers by W J Emalka in
Google Scholar
PubMed
Search for other papers by H U Daraniyagala in
Google Scholar
PubMed
.d. ) 12.80 (8.50) 2.37 (0.95) 0.008 Patients in both groups were on antihypertensives, diuretics, aspirin, statins, vitamin D, 1-alpha cholecalciferol, vitamin C, ferrous sulfate, multivitamins, folic acid, proton pump inhibitors, oral
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Christine Rode Andreasen in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Andreas Andersen in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Filip Krag Knop in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Tina Vilsbøll in
Google Scholar
PubMed
tested in the other CVOTs ( Table 1 ), the short follow-up period of 2 years and the highest percentage of participants on statin therapy ( Table 2 ). The EXSCEL trial did not find any significant difference in the primary outcome between treatment with